Finance Roundup: Tizona, Aspyrian Raise VC Cash; Two Biotechs Ready IPOs

Immuno-oncology and targeted cancer therapies, especially when backed by seasoned drug development teams, continue to attract keen venture capital interest, as Tizona Therapeutics Inc. and Aspyrian Therapeutics Inc. demonstrated recently.